国产雷帕霉素药物洗脱支架对冠心病PCI患者血管内皮功能及心率变异性的影响OA

Objective To explore the efficacy of domestic rapamycin drug-eluting stent(DES)applied in patients with coronary heart disease(CHD)undergoing percutaneous coronary intervention(PCI).Methods The clinical data of 66 patients with CHD who underwent PCI in our hospital from October 2023 to February 2025 were retrospectively analyzed.The patients were divided into two groups according to the interventional therapy received,with 33 cases in each group.The control group was treated with paclitaxel-eluting balloon,while the observation group was treated with domestic rapamycin DES.The vascular endothelial function,heart rate variability(HRV),cardiac function and the incidence of major adverse cardiovascular events(MACE)were compared between the two groups.Results At 6 months after surgery,the flow-mediated dilation(FMD),nitric oxide(NO),standard deviation of normal sinus RR intervals within 5 minutes(SDNN),standard deviation of the average normal RR intervals within 5 minutes(SDANN),root mean square of successive RR interval differences(RMSSD),and left ventricular ejection fraction(LVEF)in the observation group were higher than those in the control group,endothelin-1(ET-1)was lower than that in the control group,and left ventricular end-diastolic diameter(LVEDD)was shorter than that in the control group(all P<0.05).No statistically significant difference was found in the incidence of MACE between the two groups(P>0.05).Conclusions Domestic rapamycin DES applied in CHD patients undergoing PCI can effectively improve their vascular endothelial function and HRV,promote cardiac function recovery,and does not increase the incidence of MACE.